Journal of Clinical Immunology

, Volume 21, Issue 3, pp 193–199 | Cite as

Cytokine Modulation with Immune γ-Globulin in Peripheral Blood of Normal Children and Its Implications in Kawasaki Disease Treatment

  • Monesha Gupta
  • Gary J. Noel
  • Marc Schaefer
  • Deborah Friedman
  • James Bussel
  • Rosemary Johann-Liang


Intravenous immune γ-globulin (IVIG) is used successfully in the treatment of Kawasaki disease, with dose-dependent rapid resolution of symptoms such as fever and irritability and a decrease in ESR, WBCs, and platelets. The mode of action of IVIG in reducing this inflammatory response is not clearly understood. Recently anticytokine antibodies in IVIG have been demonstrated. Serum levels of proinflammatory cytokines have been shown to be elevated in patients with Kawasaki disease. The cytokine interleukin-6 (IL-6) is involved in the de novo production of acute-phase proteins by hepatocytes and cause thrombocytosis and fever in response to tissue injury. Patients receiving parenteral recombinant human IL-6 have dose-dependently experienced fever, malaise, chills, and acute-phase reaction. With high IL-6 concentrations, central nervous system toxicity has also been reported and IL-6 has been thought to mediate endothelial damage. We evaluated the response of stimulated blood cells of 12 normal children to IVIG in the release of the cytokines IL-6, IL-8, TNF-α, and IL-6 receptor (sIL-6R). The levels of cytokines IL-6, IL-8, and TNF-α (but not sIL-6R) in peripheral blood induced by stimulation with LPS were markedly reduced (P < 0.008) within 3 hr when incubated with IVIG compared to without IVIG. Thus we demonstrated that cells of normal children respond to IVIG in vitro by reducing cytokines such as IL-8, TNF-α, and IL-6 without affecting the level of receptor sIL-6R during an acute inflammatory response. We also found significantly higher IL-6 levels in children with Kawasaki disease compared to children with blood culture-negative febrile illnesses. In five children with Kawasaki disease we measured serum IL-6 before and after IVIG and assessed the clinical response to IVIG therapy. Therapy with IVIG was followed by a rapid resolution of symptoms in Kawasaki disease, with a significant decrease in serum IL-6. The attenuation of proinflammatory cytokine responses, especially IL-6, following infusions of IVIG may play an integral role in the rapid resolution of symptoms and decrease in the acute-phase proteins in children with Kawasaki disease. Cells of normal children were found to respond to the IVIG in a manner similar to that of the Kawasaki children.

Pediatrics whole-blood assay interleukin-6 (IL-6) interleukin-8 tumor necrosis factor-α soluble IL-6 receptor Kawasaki disease intravenous immune γ-globulin 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Furukawa S, Matsubara T, Yone K, Hirano Y, Okamura K, Yabuta K: Kawasaki disease differs from anaphylactoid purpura and measles with regard to tumor necrosis factor alpha and interleukin-6 in serum. Eur J Pediatr 151:44-47, 1992Google Scholar
  2. 2.
    Eberhard BA, Andersson U, Laxer RM, Rose V, Silverman ED: Evaluation of the cytokine response in Kawasaki disease. Pediatr Infect Dis J 14(3):199-203, 1995Google Scholar
  3. 3.
    Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, Duffy CE, et al.: The treatment of Kawasaki syndrome with intravenous gamma globulin. Engl J Med 315:341-347, 1986Google Scholar
  4. 4.
    Kimberly RP, Salmon JE, Bussel JB, Kuntz Crow M, Hilgartner MW: Modulation of mononuclear phagocytes function by intravenous g-globulin. J Immunol 132:745-750, 1984Google Scholar
  5. 5.
    Andersson U, Bjork L, Skansen-Saphir U, Andersson J: Pooled human IGG modulated cytokine production in lymphocytes and monocytes. Immunol Rev 139:21-42, 1994Google Scholar
  6. 6.
    Aukrust P, Froland SS, Liabakk NB, Muller F, Nordoy I, Haug C, Espevik T: Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 84:2136-2143, 1994Google Scholar
  7. 7.
    Svenson M, Hansen MB, Bendtzen K: Binding of cytokines to pharmaceutically prepared human immunoglobulin. J Clin Invest 92(5):2533-2539, 1993Google Scholar
  8. 8.
    Nachbaur D, Herold M, Eibl B, Glassl H, Schwaighofer H, Huber C, Gachter A: A comparative study of the in vitro immunomodulatory activity of human intact immunoglobulin (7S IVIG), F(ab′)2 fragments (5S IVIG) and Fc fragments. Evidence for post-transcriptional IL-2 modulation. Immunology 90:212-218, 1997Google Scholar
  9. 9.
    Sutterwala F, Noel GJ, Clynes R, Mosser DM: Selective suppression of interleukin-12 induction after macrophage receptor ligation. J Exp Med 185:1977-1985, 1997Google Scholar
  10. 10.
    Ross C, Svenson M, Nielsen H, Lundsgaard C, Hansen MB, Bendtzen K: Increased in vivo antibody activity against interferon α, interleukin-1α, and interleukin-6 after high-dose Ig therapy. Blood 90:2376-2380, 1997Google Scholar
  11. 11.
    Takei S, Arora YK, Walker SM: Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens. J Clin Invest 91:602-607, 1993Google Scholar
  12. 12.
    Meissner HC, Schlievert, Leung DYM: Mechanisms of immunoglobulin action: Observations on Kawasaki syndrome and RSV prophylaxis. Immunol Rev 139:109-123, 1994Google Scholar
  13. 13.
    Schiller B, Elinder G: Inflammatory parameters and soluble cell adhesion molecules in Swedish children with Kawasaki disease: Relationship to cardiac lesions and intravenous immunoglobulin treatment. Acta Paediatr 88:844-848, 1999Google Scholar
  14. 14.
    Noh GW, Lee WG, Lee W, Lee K: Effects of intravenous immunoglobulin on plasma interleukin-10 levels in Kawasaki disease. Immunol Lett 62:19-24, 1998Google Scholar
  15. 15.
    Takata Y, Seki S, Dobashi H, Takeshita S, Nakatani K, Kamezawa Y, Hiraide H, Sekine I, Yoshiioka S: Inhibition of IL-12 synthesis of peripheral blood mononuclear cells (PBMC) stimulated with bacterial superantigen by pooled human immunoglobulin: Implications for its effect on Kawasaki disease (KD). Clin Exp Immunol 114:311-319, 1998Google Scholar
  16. 16.
    Leung DYM, Burns J, Newburger J, Geha RS: Reversal of immunoregulatory abnormalities in Kawasaki syndrome by intravenous gamma globulin. J Clin Invest 79:468-472, 1987Google Scholar
  17. 17.
    Okitsu-Negishi S, Furusawa S, Kawa Y, Hashira S, Ito S, Hiruma F, Mizoguchi M, Yoshino K, Abe T: Suppressive effect of intravenous immunoglobulins on the activity of interleukin-1. Immunol Res 13:49-55, 1994Google Scholar
  18. 18.
    Myones BL, Bathori JM, Tomita S, Corydon K, Shulman ST: Intravenous IgG infusions are associated with the in vitro inhibition of classical pathway-mediated lysis of sheep red blood cells and a decrease in C4d levels in Kawasaki disease. In Proceedings of the Fourth International Symposium on Kawasaki Disease, M Takashashi, K Taubert (ed). Dallas, American Heart Association, 1993, pp 412-418Google Scholar
  19. 19.
    Suzuki H, Iizuka T, Uemura S, Koike M, Maeda J: The pathophysiological significance of serum tumor necrosis factor in Kawasaki disease. Presented at the Third International Kawasaki Disease Symposium, Tokyo. Proceeding 1988, pp 117-119Google Scholar
  20. 20.
    Suzuki H, Uemura S, Tone S, Iizuka T, Koike M, Hirayama K, Maeda J: Effects of immunoglobulin and gamma-interferon on the production of tumour necrosis factor-a and interleukin-1b by peripheral blood monocytes in the acute phase of Kawasaki disease. Eur J Pediatr 155:291-296, 1996Google Scholar
  21. 21.
    Uwno Y, Takano N, Kanegane H, Yokoi T, Yachie A, Miyawaki T, Taniguchi N: The acute phase nature of interleukin 6: Studies in Kawasaki disease and other febrile illnesses. Clin Exp Immunol 76:337-342, 1989Google Scholar
  22. 22.
    Sakaguchi M, Kato H, Nishiyori A, Sagawa K, Itoh K: Characterization of CD4+T helper cells in patients with Kawasaki disease: Preferential production of tumor necrosis factor-alpha by V beta 2-of V beta 8-CD4+ T helper cells. Clin Exp Immunol 99(2):276-282, 1995Google Scholar
  23. 23.
    Rowley AH, Gonzalez-Crussis F, Shulman S: Kawasaki syndrome. Rev Infect Dis 10:1-15, 1998Google Scholar
  24. 24.
    Takeshita S, Nakatanni K, Kawase H, Seki S, Yamammoto M, Sekine I, Yoshioka S: The role of bacterial lipopopysaccharidebound neutrophils in the pathogenesis of Kawasaki disease. J Infect Dis 179:508-512, 1999Google Scholar
  25. 25.
    Alder LBA, Morgan LA, Spickett GP: Contribution of stabilizing agents present in intravenous immunoglobulin preparations to modulation of mononuclear cell proliferation in vitro. Scand J Immunol 44:585-591, 1996Google Scholar
  26. 26.
    Abe Y, Horiuchi A, Miyake M, Kimura S: Anti-cytokine nature of natural human immunoglobulin: One possible mechanism of the clinical effect of intravenous immunoglobulin therapy. Immunol Rev 139:5-19, 1994Google Scholar
  27. 27.
    Ostermann H, Kratz-Albers K, Mesters RM, Kiehl M, Kienast J: Reciprocal changes in circulating interleukin-6 and its soluble receptor during evolving sepsis in leukocytopenic patients. J Infect Dis 176:825-828, 1997Google Scholar
  28. 28.
    Lin C, Lin C, Hwang B, Chiang B: Serial changes of serum interleukin-6, interluekin-8, and tumor necrosis factor alpha among patients with Kawasaki disease. J Pediatr 121:924-926, 1992Google Scholar
  29. 29.
    Gauldie J, Richards C, Harnish D, Lansdrop P, Baumann H: Interferon β2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte stimulating factor and regulates the major acute phase response in liver cells. Proc Natl Acad Sci USA 84: 7251, 1987Google Scholar
  30. 30.
    Geiger T, Andus T, Klapproth J, Hirano T, Kishimoto T, Heinrich PC: Induction of rat acute-phase proteins by interleukin 6 in vivo. Eur J Immunol 18:717-721, 1988Google Scholar
  31. 31.
    Nijsten, MW, de Groot ER, ten Duis HJ, Klasen HJ, Hack CE, Aarden LA: Serum levels of interleukin-6 and acute phase responses [letter]. Lancet 2:921, 1987Google Scholar
  32. 32.
    Hill RJ, Warren MK, Levin J: Stimulation of thrombopoiesis in mice by human recombinant interleukin-6. J Clin Invest 85:1242-1247, 1990Google Scholar
  33. 33.
    Stouthard JM, Goey H, de Vries EG, et al.: Recombinant human interleukin 6 in metastatic renal cell cancer: A phase II trial. Br J Cancer 73:789-793, 1996Google Scholar
  34. 34.
    Kammuller M, Ryffel B: Extrapolation of experimental safety data to humans: The interleukin-6 case. Clin Immunol Immunopathol 83:15-17, 1997Google Scholar
  35. 35.
    Keever-Taylor CA, Witt PL, Truitt RL, Ramanujam S, Borden EC, Rictch PS: Hematologic and immunologic evaluation of recombinant human interleukin-6 in patients with advanced malignant disease: Evidence for monocyte activation. J Immunother Emphasis Tumor Immunol 19:231-243, 1996Google Scholar
  36. 36.
    Bell S, Kamm MA: Antibodies to tumour necrosis factor a as treatment for Crohn's disease [commentary]. Lancet 355:858-860, 2000Google Scholar
  37. 37.
    Pisetsky DS: Tumour necrosis factor blockers in rheumatoid arthritis [Editorial]. N Engl J Med 342:810-811, 2000Google Scholar

Copyright information

© Plenum Publishing Corporation 2001

Authors and Affiliations

  • Monesha Gupta
    • 1
  • Gary J. Noel
    • 1
  • Marc Schaefer
    • 1
  • Deborah Friedman
    • 2
  • James Bussel
    • 2
  • Rosemary Johann-Liang
    • 1
  1. 1.Department of Pediatrics, Division of CardiologyNew York Presbyterian Hospital–Weill Medical College of Cornell UniversityNew York
  2. 2.New York Presbyterian Hospital–Weill Medical College of Cornell UniversityNew York

Personalised recommendations